CXCL9 and melanoma: Higher levels of CXCL9, CXCL10, and CXCL11 were also detected in melanoma patients’ tumors following treatment with ipilimumab, an antagonistic antibody against cytotoxic T-lymphocyte-associated protein 4 (CTLA4), another inhibitory receptor expressed by T cells [46].